Cart
sales@molnova.com
Finerenone
CAS No. 1050477-31-0
Finerenone( BAY 94-8862 | BAY 948862 )
Catalog No. M10243 CAS No. 1050477-31-0
Finerenone (BAY 94-8862) is a potent, selective, orally available mineralocorticoid receptor (MR) antagonist with IC50 of 18 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 67 | In Stock |
|
| 10MG | 104 | In Stock |
|
| 25MG | 209 | In Stock |
|
| 50MG | 337 | In Stock |
|
| 100MG | 537 | In Stock |
|
| 200MG | 610 | In Stock |
|
| 500MG | 896 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFinerenone
-
NoteResearch use only, not for human use.
-
Brief DescriptionFinerenone (BAY 94-8862) is a potent, selective, orally available mineralocorticoid receptor (MR) antagonist with IC50 of 18 nM.
-
DescriptionFinerenone (BAY 94-8862) is a potent, selective, orally available mineralocorticoid receptor (MR) antagonist with IC50 of 18 nM; displays excellent selectivity (>500-fold) versus GR, AR, and PR, also shows no L type Ca2+ channel activity; elicits a significant and dose-dependent increase in the urinary sodium/potassium ratio in vivo, with a MED of 0.3 mg kg1 p.o.; exhibits three- to tenfold greater potency and higher efficacy in acute rat natriuresis model compared with eplerenone, demonstrates potential for the treatment of chronic heart failure (CHF).Heart FailurePhase 3 Clinical(In Vivo):Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Fr?mter (MWF) rat.
-
In Vitro——
-
In VivoFinerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Fr?mter (MWF) rat. Animal Model:Twelve-week-old MWF ratDosage:10 mg/kg Administration:P.o.; daily for 4 weeks Result:Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model.Animal Model:Twelve-week-old MWF ratDosage:10 mg/kg Administration:P.o.; daily for 4 weeks Result:Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model.
-
SynonymsBAY 94-8862 | BAY 948862
-
PathwayNuclear Receptor/Transcription Factor
-
TargetMLR
-
RecptorMLR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1050477-31-0
-
Formula Weight378.432
-
Molecular FormulaC21H22N4O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 200 mg/mL (528.51 mM)
-
SMILESO=C(C1=C(C)NC2=C(C(OCC)=NC=C2C)[C@@H]1C3=CC=C(C#N)C=C3OC)N
-
Chemical Name(4S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. B?rfacker L, et al. ChemMedChem. 2012 Aug;7(8):1385-403.
2. Kolkhof P, et al. J Cardiovasc Pharmacol. 2014 Jul;64(1):69-78.
3. Filippatos G, et al. Eur Heart J. 2016 Jul 14;37(27):2105-14.
4. Amazit L, et al. J Biol Chem. 2015 Sep 4;290(36):21876-89.
molnova catalog
related products
-
Apararenone
Apararenone (MT-3995) is a novel potent, selective non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.
-
PF-03882845
PF-03882845 is highly potent, selective, nonsteroidal, orally bioavailable Mineralocorticoid receptor antagonist with IC50 of 4.5 nM.
-
AZD 9977
AZD9977 is a novel, first-in-class, selective and oral mineralocorticoid receptor (MR) modulator with pKi of 7.5, shows little to no affitnity for GR, PR and AR (pIC50<5.5).
